IJCM  Vol.3 No.5 , September 2012
Oral Administration Recombinant Bifidobacterium-LTB (B Subunit of Heat-Labile Enterotoxin) Enhances the OVA (Ovalbumin)-Specific sIgA in Jejunal Mucosa of Sprague-Dawley (SD) Rat
ABSTRACT
The LTB of enterotoxigenic Escherichia coli (ETEC) expressed in Bifidobacterium infantis (BI) has been testified as mucosal adjuvant with co-vaccination BI-CfaB (the major fimbrial subunit) together in vivo in our previous study. In order to investigate the mucosal adjuvant effect of BI-LTB to purified antigens, we oral vaccinated SD rats with recombinant BI-LTB plus OVA (rBI-LTB + OVA), and wild type BI plus OVA (wBI + OVA), OVA and PBS (Phosphate buffered saline) were vaccinated as controls, respectively. The OVA-specific sIgA in jejunal mucosa and specific IgG in serium were measured with ELISA (Enzyme-linked immunosorbent assay) and the sIgA producing cells were detected with immunohistochemistry technology (IHC) and Qwin image manipulation tools subsequently. The results shown rBI-LTB could stimulate SD rats produce high titer OVA-specific sIgA in rBI-LTB + OVA group and the OVA-specific sIgA titer in rBI-LTB + OVA group was found significant greater than that of the wBI + OVA group or OVA single group (p < 0.05). However no such significant difference was detected between the group wBI + OVA and OVA. IHC results suggested that intestinal mucosa and submucosa was the main field of sIgA secretion. These results suggested that recombinant LTB expression in BI could be used as a wide range mucosal adjuvant with different form antigens.

Cite this paper
Y. Ma, Y. Hao, W. Tang, R. Wang, F. Yi, Y. Bu, L. Zhang and F. Song, "Oral Administration Recombinant Bifidobacterium-LTB (B Subunit of Heat-Labile Enterotoxin) Enhances the OVA (Ovalbumin)-Specific sIgA in Jejunal Mucosa of Sprague-Dawley (SD) Rat," International Journal of Clinical Medicine, Vol. 3 No. 5, 2012, pp. 387-393. doi: 10.4236/ijcm.2012.35073.
References
[1]   Sanchez J, Holmgren J. Cholera toxin--a foe & a friend. Indian J Med Res 2011;133(2):153-63.

[2]   Yamamoto T, Yokota T. Plasmids of enterotoxigenic Escherichia coli H10407: evidence for two heat-stable enterotoxin genes and a conjugal transfer system. J Bacteriol 1983; 153, 1352–1360.

[3]   Yamamoto T, Tamura T, Yokota T. Primary structure of heat-labile enterotoxin produced by Escherichia coli pathogenic for humans. J Biol Chem 1984; 259, 5037–5044.

[4]   da Hora VP, Conceicao FR, Dellagostin OA, Doolan DL. Non-toxic derivatives of LT as potent adjuvants. Vaccine 2011; 29(8): 1538-44.

[5]   Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005; 23(15):1804-1813.

[6]   Williams NA. Immune modulation by the cholera-like enterotoxin B-subunits: from adjuvant to immunotherapeutic. Int J Med Microbiol 2000; 290(4-5):447-53.

[7]   Nashar TO, Betteridge ZE, Mitchell RN. Evidence for a role of ganglioside GM1 in antigen presentation: binding enhances presentation of Escherichia coli enterotoxin B subunit (EtxB) to CD4(+) T cells. Int Immunol 2001;13(4):541-51.

[8]   Fingerut E, Gutter B, Goldway M, Eliahoo D, Pitcovski J. B subunit of E. coli enterotoxin as adjuvant and carrier in oral and skin vaccination. Vet Immunol Immunopathol 2006; 112: (3–4):253–63.

[9]   Ma YP, Luo YL, Huang XP, Song FZ, Liu GL. Construction of Bifidobacterium infantis as a live oral vaccine that expresses antigens of the major fimbrial subunit (CfaB) and LTB from Enterotoxigenic Escherichia coli. Microbiol 2012;158:498-504.

[10]   Hayward CMM, O’Gaora P, Young DB, Griffin GE, Thole J, Hirst TR, Castello-Branco LRR, Lewis DJM. Construction and murine immunogenicity of recombinant Bacille Calmette Guerin vaccine expressing the B subunit of Escherichia coli heat labile enterotoxin. Vaccine 1999; 17, 1272–1281.

[11]   Goto N, Maeyama JI, Yasuda Y, Isaka M, Matano K, Kozuka S, Taniguchi T, Miura Y, Okhuma K, Tochikubo K. Safety evaluation of recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant. Vaccine 2000; 18 (20), 2164–2171.

[12]   Isaka M, Yasuda Y, Kozuka S, Taniguchi T, Matano K, Maeyama J, Komiya T, Ohkuma K, Goto N, Tochikubo K. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine 1999; 18, 743–751.

[13]   Slos P, Dutot P, Reymund J, Kleinpeter P, Prozzi D, Kieny MP, Delcour J, Mercenier A, Hols P. Production of cholera toxin B subunit in Lactobacillus. FEMS Microbiol Lett 1998; 169, 29-36.

[14]   Liljeqvist S, Samuelson P, Hansson M, Nguyen TN, Binz H, Stahl S. Surface display of the cholera toxin B subunit on Staphylococcus xylosus and Staphylococcus carnosus. Appl Environ Microbiol 1997; 63 (7), 2481-2488.

[15]   Fingerut E, Gutter B, Meir R, Eliahoo D, Pitcovski J. Vaccine and adjuvant activity of recombinant subunit B of E. coli enterotoxin produced in yeast. Vaccine 2005; 23 (38), 4685–4696.

[16]   Guarner F, Malagelada JR. Gut flora in health and disease. The Lancet 2003; 361(9356): 512-519.

[17]   da Silva Ramos Rocha A, Conceicao FR, Grassmann AA, Lagranha VL, Dellagostin OA. B subunit of Escherichia coli heat-labile enterotoxin as adjuvant of humoral immune response in recombinant BCG vaccination. Can J Microbiol 2008; 54(8):677-86.

[18]   Conceicao FR, Moreira AN, Dellagostin OA. A recombinant chimera composed of R1 repeat region of Mycoplasma hyopneumoniae P97 adhesin with Escherichia coli heat-labile enterotoxin B subunit elicits immune response in mice. Vaccine 2006; 24 (29-30):5734- 5743.

[19]   Weltzin R, Guy B, Thomas Jr WD, Giannasca PJ, Monath TP. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection. Infect Immun 2000; 68 (5):2775-82.

[20]   Nashar TO, Hirst TR, Williams NA. Modulation of B-cell activation by the B subunit of Escherichia coli enterotoxin: receptor interaction up-regulates MHC class II, B7, CD40, CD25 and ICAM-1. Immunol 1997; 91(4):572-8.

[21]   McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992;10, 75-88.

[22]   Liu JK, Hou XL, Wei CH, Yu LY, He XJ, Wang GH, Lee JS, Kim CJ. Induction of immune responses in mice after oral immunization with recombinant Lactobacillus casei strains expressing enterotoxigenic Escherichia coli F41 fimbrial protein. Appl Envir Microbiol 2009; 75(13) : 4491-4497.

[23]   Medina M, Vinti?i E, Villena J, Raya R, Alvarez S. Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infections. Bioeng Bugs 2010; 1(5):313-325.

[24]   Wei CH, Liu JK, Hou XL, Yu LY, Lee JS, Kimd CJ. Immunogenicity and protective efficacy of orally or intranasally administered recombinant Lactobacillus casei expressing ETEC K99. Vaccine 2010; 28(24): 4113-4118.

[25]   Wells J. Mucosal vaccination and therapy with genetically modified lactic Acid bacteria. Annu Rev Food Sci Technol 2011; 2:423-45.

[26]   Yamamoto S, Wada J, Katayama T, Jikimoto T, Nakamura M, Kinoshita S, Lee KM, Kawabata M, Shirakawa T. Genetically modified Bifidobacterium displaying Salmonella antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model. Vaccine 2010; 28(41):6684-91

[27]   Sekine K, Watanabe-Sekine E, Toida T, Kasashima T, Kataoka T, Hashimoto Y. Adjuvant activity of the cell wall of Bifidobacterium infantis for in vivo immune responses in mice. Immunopharmacol Immunotoxicol 1994; 16(4):589-609.

[28]   Schmidt EG, Claesson MH, Jensen SS, Ravn P, Kristensen NN. Antigen-presenting cells exposed to Lactobacillus acidophilus NCFM, Bifidobacterium bifidum BI-98, and BI-504 reduce regulatory T cellactivity. Inflamm Bowel Dis 2010, 16(3):390-400.

[29]   Paineau D, Carcano D, Leyer G, Darquy S, Alyanakian MA, Simoneau G, Bergmann JF, Brassart D, Bornet F, Ouwehand AC. Effects of seven potential probiotic strains on specificimmune responses in healthy adults:a double-blind, randomized, controlled trial. FEMS Immunol Med Microbiol 2008; 53(1):107-13.

[30]   Zhao LL, Cheng Q. The influence of whole peptidoglycan of Bifidobacterium on interleukin-12 produced by dendritic cells derived from bone marrow of mice in vitro. ZHONGGUO WEISHENGTAIXUE ZAZHI. 2009; 21(10): 896-901.

[31]   Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W, Groshen SL, Weber JS. Alum with interleu-kin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 2007; 13 (1), 215-222.

[32]   Jacobson MA, Sinclair E, Bredt B, Agrillo L, Black D, Epling CL, Carvidi A, Ho T, Bains R, Girling V, Adler SP. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine 2006; 24 (25), 5311-5319.

[33]   Wright AK, Christopoulou I, El Batrawy S, Limer J, Gordon SB. rhIL-12 as adjuvant augments lung cell cytokine responses to pneumococcal whole cell antigen. Immunobiol 2011; 216(10):1143-7.

[34]   Dong P, Yang Y, Wang WP. The role of intestinal bifidobacteria on immune system development in young rats. Early Hum Dev 2010; 86(1):51-8.

[35]   Boyaka PN, Ohmura M, Fujihashi K, Koga T, Yamamoto M, Kweon MN, Takeda Y, Jackson RJ, Kiyono H, Yuki Y, McGhee JR. Chimeras of Labile Toxin One and Cholera Toxin Retain Mucosal Adjuvanticity and Direct Th Cell Subsets Via Their B Subunit. J Immunol 2003; 170:454-462.

[36]   Yamamoto S, Kiyono H, Yamamoto M, Imaoka K, Fujihashi K, Van Ginkel FW, Noda M, Takeda Y, McGhee JR. A nontoxic mutant of Cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 1997; 94(10):5267-72.

 
 
Top